ZIOPHARM Oncology, Inc. Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval For Phase 1 Study Of Ad-RTS-IL-12 In Subjects With Recurrent Or Progressive Glioblastoma

Published: Dec 06, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON, Dec. 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral activator, in subjects with recurrent or progressive glioblastoma or grade III malignant glioma (brain cancer). ZIOPHARM has announced plans to launch a Phase 1 study of Ad-RTS-IL-12 in malignant glioma in the first half of 2014. The Company is currently studying Ad-RTS-IL-12 in Phase 2 studies in melanoma and breast cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news